Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma

PartnershiplacutamabPositive

AI Analysis

Summary

Sobi and Innate Pharma announced a strategic partnership to license lacutamab for T-cell lymphoma, enabling initiation of the TELLOMAK-3 confirmatory trial. The collaboration combines resources of both companies to advance the candidate in this indication.

Clinical Trial Data

Outcome Details

Strategic partnership to enable initiation of TELLOMAK-3 confirmatory trial

Importance:7/10

Sentiment:

0.60

partnershiplicensinglacutamabT-cell lymphomaconfirmatory trial

Related Companies

$SOBI.ST $IPHA

Read the original article

Published by PR Newswire Biotech on August 10, 2026 6:32 AM

Read Original